Understand your risk of prostate cancer
MiCheck® Prostate is a next-generation test to aid in the identification of aggressive prostate cancer risk1
The gold standard for assessing aggressive prostate cancer risk
Quick, non-invasive, highly sensitive and specific blood test
No out of pocket charges
Simple to order test
Exceptional sensitivity
Avoid unnecessary biopsies
Concerned about prostate cancer?
Learn how MiCheck® Prostate uses a scientifically validated algorithm to provide a more accurate assessment of aggressive prostate cancer1 risk compared to traditional methods.
How MiCheck® Prostate can help
Detects up to 95% of clinically significant cancers2
Potentially reducing up to 50% of biopsies2
Check if you are eligible for MiCheck® Prostate
Determine if you are eligible for MiCheck® Prostate, an advanced follow-up blood test following an abnormal PSA and/or DRE result.
Questions about
MiCheck® Prostate?
Find answers to your questions, and book a free discovery call with a Care Concierge to see if MiCheck® Prostate may be the right choice for you.
Frequently asked questions
MiCheck® Prostate is a test specifically designed to detect aggressive prostate cancer.
MiCheck® Prostate is a scientifically validated algorithm that calculates how likely it is that you have aggressive prostate cancer. To do this, it uses results from:your digital rectal examination (DRE)levels of three biomarkers specific to prostate cancer in a blood sample – total prostate specific antigen (PSA), free PSA, and Human Epididymal Protein 4 (HE4).The MiCheck® Prostate algorithm combines these results to calculate a MiCheck® Prostate Percentage Risk Score. This score indicates the likelihood of aggressive prostate cancer (Gleason score >7) being present, versus a non-cancerous condition or less harmful form of cancer.
Not at the moment.
Your Urologist will discuss the test result with you, together with other relevant data (e.g. family history). This will allow shared decision making between you and the Urologist as to whether you should proceed to a prostate biopsy.
The risks are the same as having a blood test.
Most test results are reported within 1 week of you providing the blood sample.
MiCheck® Prostate is covered under a CPT code. There is no out of pocket cost.
You should discuss with your Urologist the frequency of MiCheck® Prostate testing.
References
Shore et al (2020) A comparison of Prostate Health Index, total PSA, %free PSA and proPSA in a contemporary US population – the MiCheck-01 prospective trial. Urol Oncol. 38(8):683e1-683e10.
Shore at al (2023).